Gymnema sylvestre is a traditional plant supplement whose leaf extracts are used as oral lozenges to block sweet taste or as oral capsules before meals for blood sugar and cholesterol control. It is not a direct longevity therapy: lozenges briefly block sweetness without reliably reducing ongoing sugar intake, while capsules modestly lower elevated blood sugar, triglycerides, and cholesterol, with digestive, low blood sugar, and rare liver risks. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting Plasma Glucose (FPG) | 70–99 mg/dL (3.9–5.5 mmol/L) | Efficacy marker and hypoglycemia safety check: expected to decrease after ≥ 12 weeks (measured after an 8–12 hour overnight fast). |
| 2-Hour Oral Glucose Tolerance Test (OGTT) Glucose | < 140 mg/dL (< 7.8 mmol/L) | Efficacy marker: primary postprandial glycemic target in IGT (measured 2 hours after a 75 g morning glucose load). |
| Glycated Hemoglobin (HbA1c) | < 5.7% (reference 4.0–5.6%) | Efficacy marker: tracks 8–12 week integrated blood glucose change (no fasting required; rechecked at 12 weeks). |
| Fasting Triglycerides (TG) & Total Cholesterol (TC) | TG < 150 mg/dL (< 1.7 mmol/L); TC < 200 mg/dL (< 5.2 mmol/L) | Efficacy marker: expected to decrease over 8–12 weeks (measured after a 9–12 hour fast alongside LDL-C and VLDL-C). |
| Alanine Aminotransferase (ALT) & Aspartate Aminotransferase (AST) | ALT 7–56 U/L; AST 8–33 U/L | Safety check: screens for rare idiosyncratic DILI (baseline > 2× ULN excludes trial participation; protocols discontinue use above 3× ULN). |
| Serum Creatinine | ≤ 1.5 mg/dL (reference 0.6–1.2 mg/dL) | Safety check: verifies baseline renal function before systemic use (> 1.5 mg/dL or renal disease excludes trial participation). |
Cadence: Baseline CMP, glycemic, and lipid panel before systemic initiation; daily capillary blood glucose during weeks 1–2 with concomitant antidiabetic drugs; ALT and AST at 6 and 12 weeks; core efficacy biomarkers (FPG, HbA1c, TG, TC, and 2-hour OGTT glucose) at 12 weeks, then every 6 months thereafter.